KYMR (NASDAQ) director records large 10b5-1 sales and RSU vesting
Rhea-AI Filing Summary
Kymeta Therapeutics, Inc. reported proposed and recent transactions involving Common Stock. The filing lists shares acquired upon vesting of Restricted Stock Units on 05/22/2026 and multiple 10b5-1 sales by Jeremy Chadwick between 03/02/2026 and 04/22/2026, with individual sale sizes shown in the excerpt.
The excerpt shows specific sale entries such as 91,250 shares on 03/23/2026 and other transactions ranging from 300 to 91,250 shares, with associated gross proceeds listed for many trades.
Positive
- None.
Negative
- None.
Insights
Multiple pre-arranged sales recorded under a trading plan; vesting and sales are administrative compensation and liquidity events.
The filing lists RSU vesting on 05/22/2026 and numerous 10b5-1 sales by Jeremy Chadwick dated from 03/02/2026 to 04/22/2026. The presence of a 10b5-1 plan implies transactions executed under a pre-established plan; the excerpt labels several entries explicitly as 10b5-1 Sales.
Cash treatment and whether sales were part of the Form 144 registration or prior dispositions are not detailed in the excerpt; subsequent filings or confirmations would clarify proceeds recipient and any remaining holdings.
Sale volumes vary widely; a few large dispositions (e.g., 91,250 shares) dominate the reported activity.
The excerpt provides per-trade share counts and gross proceeds for many entries, for example 91,250 shares for $7,063,733.26 on 03/23/2026, and smaller trades such as 300 shares on 04/22/2026. These figures form the transaction record visible in this filing.
Post-transaction holdings and whether any sales were for tax withholding related to RSU vesting are not specified in the provided excerpt; further disclosure would show remaining insider position and tax treatments.